Company Overview and News

27
Analog Devices, Inc. (ADI) CEO Vincent Roche on Q2 2018 Results - Earnings Call Transcript

2018-05-30 seekingalpha
Good morning, and welcome to the Analog Devices Second Quarter Fiscal Year 2018 Earnings Conference Call, which is being audio webcast via telephone and over the web.
ADI LLTC

48
RBC Stays With 3 Big Semiconductor Stocks Despite Recent Concerns

2018-05-02 247wallst
If there is any industry for which red flags are starting to fly above most Wall Street firms, it’s semiconductors, and with good reason. Semiconductor stocks have produced blistering results over the past few years, and experienced investors are well aware of the cyclical nature of that industry. Without using the dreaded “It’s different this time,” it should be noted that demand in many new areas has skyrocketed and is expected to remain.
TXN ADI LLTC QCOM

27
SunTrust Stays Very Cautious on Semiconductors: Just 5 to Buy Now

2018-04-25 247wallst
All great cycles come to an end, or at the minimum, slow down to more normal growth, and in the case of the semiconductors, it has been the kind of run that few tech sectors have seen in years. While the future remains bright, it may not be the white-hot bright of the past five years that produced outsized gains for investors.
ADI LLTC

208
5 Semiconductor Stocks to Buy With Limited Exposure to Apple

2018-04-23 247wallst
While Apple Inc. (NASDAQ: AAPL) is a dominant technology player, it also tends to have peaks and valleys in its various business lines, which can expose vendors to inconsistent orders and earnings. Plus, the company announced recently it is planning to use its own chips in Macintosh computers starting in 2020. So for technology investors looking to stay on what has been a very hot semiconductor ride, it may make sense to focus on companies with little or no exposure to Apple.
CY AAPL ADI LLTC

393
Top 10 Power Ranking Divvy Techs

2018-04-10 seekingalpha
With Facebook (FB) and Amazon (AMZN) getting hit from right left and center these days, investors pretty much keep their focus on the FAANG. When we think of tech stocks, we often imagine a bunch of geeks typing on their computer with 3 screens in front of them. We also imagine young, hip and fast-moving companies with great potential to bring triple digit returns in our portfolio.
TXN OTEX MA STX V AMZN OTC AAPL AVGO ADI MSFT LLTC INTC

36
5 Stocks to Buy as Capital Spending Poised to Jump in 2018

2018-03-20 247wallst
When economic conditions are unsure, and there is any sort of worry around, both companies and consumers are generally reluctant to spend money, and with good reason. Who wants to put their capital at risk if there is a potential for an economic downturn like a recession? That’s when excess cash goes into the bank for the proverbial rainy day.
ADI LLTC CMC

35
Analog Devices Prices Senior Notes, Gets Moody's Baa1 Rating

2018-03-12 zacks
Leading semiconductor company Analog Devices Inc. (ADI - Free Report) recently announced an offering of senior unsecured notes aggregating $750 million. These notes have been issued in two tranches of different amounts with varying coupon rates and maturities.
BRC TER BRY ADI LLTC PETS

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Silicon Investor Message Boards

This table lists all message boards related to LLTC / Linear Technology Corp. on message board site Silicon Investor.

Linear Technology Corporation ADI - Analog Devices vs. LLTC Linear Technology
Linear Tech (LLTC)
CUSIP: 535678106